Telerobotic surgery, once confined to experimental demonstrations, is now gaining traction in clinical practice, and SS Innovations International (NASDAQ: SSII) is positioning itself at the forefront of this shift. According to a recent MedTech Dive report, the company's SSi Mantra system has been used in 195 robotic telesurgeries as of September 28, 2026, including cardiac procedures and long-distance operations. This milestone underscores the growing viability of remote surgery, which could expand access to specialized care in underserved regions.
Dr. Sudhir Srivastava, founder and CEO of SS Innovations, told MedTech Dive that robotic surgery is inherently a form of teleoperation, and the key technical challenge is determining how much distance can be introduced without compromising responsiveness. The company's progress suggests it is answering that question: its installed base reached 244 SSi Mantra systems as of September 28, up 45% from the end of 2025, while cumulative procedures climbed to 14,503. Such growth indicates increasing adoption of the platform across hospitals and surgical centers.
The SSi Mantra system has expanded into 12 countries, with recent cardiac-surgery programs launched in Colombia and Sri Lanka, and a new program established at HCG Hospital in Ahmedabad. These developments highlight the global reach of telerobotic surgery and its potential to bridge gaps in surgical expertise. For patients in remote or developing areas, the ability to undergo complex procedures without traveling to major medical hubs could be transformative. For the healthcare industry, it signals a shift toward more distributed surgical care models.
SS Innovations is currently pursuing U.S. FDA clearance and European Union CE marking, aiming to enter additional international markets. Regulatory approval in these regions would not only validate the technology but also accelerate its adoption among U.S. and European hospitals. The MedTech Dive article examined these regulatory and infrastructure questions, noting that telerobotic surgery is advancing worldwide and prompting debate about whether the U.S. will embrace it. The report featured SS Innovations alongside larger medical-device companies and emerging robotics developers, as detailed in the https://ibn.fm/4ZLvL coverage.
For investors, the company's operational metrics offer tangible evidence of commercial traction. The 45% increase in installed systems and the rising procedure volume suggest that SS Innovations is not merely a speculative player but one with a growing installed base and recurring revenue potential from consumables and service. However, risks remain, including the uncertainties inherent in obtaining FDA clearance and CE marking, as well as competition from established surgical robotics giants. The company's forward-looking statements acknowledge these risks, and potential investors should review the full disclaimers at https://IBN.ai/Disclaimer.
As telerobotic surgery gains ground, SS Innovations' ability to accumulate clinical experience and expand geographically will be critical. The company's newsroom at https://ibn.fm/SSII provides ongoing updates on its progress. With remote procedures becoming more common, the implications for global healthcare are profound: patients could receive timely, high-quality surgical care regardless of location, and hospitals could leverage expert surgeons across distances. SS Innovations appears well-positioned to capitalize on this trend, provided it navigates the regulatory and competitive landscape successfully. The original release can be viewed at www.newmediawire.com.
